MAPK
MAPKs are a family of protein kinases involved in a variety of cellular processes, including growth, proliferation, differentiation, and stress responses. The MAPK signaling pathway consists of several tiers, including ERK, JNK, and p38 MAPKs, each playing distinct roles in cellular function. Dysregulation of MAPK signaling is linked to cancer, inflammatory diseases, and metabolic disorders. At CymitQuimica, we offer a wide array of MAPK inhibitors and activators to support your research in cell biology, signal transduction, and disease mechanisms.
Found 892 products of "MAPK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
MRTX849 acid
CAS:MRTX849 acid, used to make PROTAC LC-2, effectively degrades KRAS G12C at 0.25-0.76 μM DC50.Formula:C34H37ClFN7O4Color and Shape:SolidMolecular weight:662.16Brimarafenib
CAS:Brimarafenib is a selective RAF dimerization inhibitor, which can inhibit BRAF and CRAF, and exhibits inhibitory effects on a variety of RAF mutations.Formula:C24H17F3N4O4Purity:98.32%Color and Shape:SolidMolecular weight:482.41KRAS G12D inhibitor 16
CAS:KRAS G12D inhibitor 16 targets KRAS G12D with IC50 of 0.7 nM and mutant form at 0.35 μM, useful in various cancer studies.Formula:C32H39IN6O3Color and Shape:SolidMolecular weight:682.59pan-KRAS degrader 1
CAS:Pan-KRAS degrader 1 (Compound 1) is a broad-spectrum KRAS degrader, exhibiting an inhibitory constant Ki value of 25 nM against KRASG12V as determined by surface plasmon resonance (SPR). Additionally, this compound demonstrates antitumor activity.Formula:C22H26N8OSColor and Shape:SolidMolecular weight:450.56(S)-JDQ-443
CAS:(S)-JDQ-443, an isomer of JDQ-443, is a selective, potent oral KRAS G12C inhibitor with antitumor properties.Formula:C29H28ClN7OColor and Shape:SolidMolecular weight:526.03KRAS inhibitor-34
CAS:KRAS inhibitor-34 (compound 27) is a KRAS inhibitor with an IC50 of 6.4 nM and is utilized in oncological research.Formula:C43H41F3N6O3Color and Shape:SolidMolecular weight:746.82KRAS G12D inhibitor 11
CAS:KRAS G12D inhibitor 11 targets KRAS G12D in cancer research (patent WO2021108683A1, compound 52).Formula:C29H38BN5O3Color and Shape:SolidMolecular weight:515.45Refametinib R enantiomer
CAS:Refametinib R enantiomer (RDEA119 R enantiomer) is an MEK inhibitor with an EC50 of 2.0-15 nM.Refametinib (R enantiomer) has anticancer activity and can be used
Formula:C19H20F3IN2O5SPurity:99.86%Color and Shape:SolidMolecular weight:572.34KRAS G12D inhibitor 9
CAS:KRAS G12D inhibitor 9 targets RAS protein, key in growth, showing promise against KRAS G12D cancer.Formula:C33H43N7O2Color and Shape:SolidMolecular weight:569.74LZTR1-KRAS modulator 1
CAS:LZTR1-KRAS modulator 1 is a regulator of the KRAS-LZTR1 interaction, enhancing the recruitment of the LZTR1-KRAS complex.Formula:C11H11Cl2NOColor and Shape:SolidMolecular weight:244.12KRAS inhibitor-32
CAS:KRAS inhibitor-32 (compound 139A) is a KRAS inhibitor utilized in cancer research.Formula:C29H35FN10OS2Color and Shape:SolidMolecular weight:622.78KRASG12C IN-12
CAS:KRASG12C IN-12 (compound-1) acts as an inhibitor of KRASG12C. It forms a ternary complex with intracellular CYPA and the activated mutant of KRASG12C.Formula:C29H39N5O6S2Color and Shape:SolidMolecular weight:617.78KRAS G12D inhibitor 19
CAS:KRAS G12D inhibitor 19 (Compound 7) is used in cancer research [1]. As a specific inhibitor of KRAS G12D, it targets and potentially suppresses this mutation, which is frequently associated with various cancers.Formula:C35H34F2N6O3Color and Shape:SolidMolecular weight:624.68KRAS ligand 3
CAS:KRAS ligand 3 (compound 1), a BTX-6654 target-binding ligand, exhibits synergistic tumor growth inhibition through its capacity to bind a KRAS inhibitor [1].Formula:C24H28F3N5Color and Shape:SolidMolecular weight:443.51PAT-IN-1
CAS:PAT-IN-1, a protein acyl transferases (PAT) inhibitor, competitively inhibits Erf2 autopalmitoylation (WO2017011518A1; compound 13) [1].Formula:C45H68N4OColor and Shape:SolidMolecular weight:681.05Calderasib
CAS:Calderasib (MK-1084) is a selective KRAS G12C inhibitor (IC50 1.2 nM) with anticancer activity, usable as monotherapy or combined with PD-1 inhibitorsFormula:C32H31ClF2N6O4Purity:98.69%Color and Shape:SolidMolecular weight:637.08BBO-8520
CAS:BBO-8520 is a dual KRASG12C inhibitor that blocks ON and OFF states, disables effector binding, suppresses signaling, and induces tumor regression.Formula:C35H33F6N7O2SPurity:97.879%Color and Shape:SolidMolecular weight:729.74COTI-219
CAS:COTI-219 is an oral inhibitor of KRAS with antitumor properties [1].Formula:C17H18N6SColor and Shape:SolidMolecular weight:338.43pan-KRAS-IN-6
CAS:Pan-KRAS-IN-6 (compound 12) is a potent pan-KRAS inhibitor, with IC50 values of 9.79 nM for Kras G12D and 6.03 nM for Kras G12V.Formula:C29H30ClF3N6O3SColor and Shape:SolidMolecular weight:635.10KRASG12D-IN-3-d3
CAS:KRASG12D-IN-3-d3 is the deuterium labeled KRASG12D-IN-3. KRASG12D-IN-3 (compound Z1084) is a KRASG12D inhibitor with oral bioactivity that can effectively inhibit the growth of tumor cells AGS and AsPC-1, with IC50 values of 0.38 nM and 1.23 nM, respectively.Formula:C31H27D3ClF6N7O2Color and Shape:SoildMolecular weight:685.08
